Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Aerts

Showing results (171-180 of 360) with videos related to

Pageof 36
Sort By:
Neurobiology of Disease|March 16, 2019
Cytosolic glucosylceramide regulates endolysosomal function in Niemann-Pick type C diseaseSimon Wheeler, Per Haberkant, Meenakshi Bhardwaj, et al.
The Journal of Organic Chemistry|January 25, 2007
Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in manTom Wennekes, Richard J B H N van den Berg, Wilma Donker, et al.
Journal of Lipid Research|April 9, 2020
Skin barrier lipid enzyme activity in Netherton patients is associated with protease activity and ceramide abnormalitiesJeroen van Smeden, Hanin Al-Khakany, Yichen Wang, et al.
Carbohydrate Research|August 9, 2014
Design and synthesis of 4'-O-alkyl-chitobiosyl-4-methylumbelliferone as human chitinase fluorogenic substratesBoudewijn A Duivenvoorden, Karen Ghauharali, Saskia Scheij, et al.
Molecular Genetics and Metabolism|February 24, 2020
Biochemical and imaging parameters in acid sphingomyelinase deficiency: Potential utility as biomarkersEline C B Eskes, Barbara Sjouke, Frédéric M Vaz, et al.
Journal of Inherited Metabolic Disease|September 20, 2007
Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safeJ Cox-Brinkman, R G M Timmermans, F A Wijburg, et al.
Journal of Inherited Metabolic Disease|October 14, 2008
Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type IIIJ Cox-Brinkman, M J van Breemen, B T van Maldegem, et al.
Journal of Proteomics|February 2, 2015
Potential of UCHL1 as biomarker for destruction of pancreatic beta cellsB Brackeva, V De Punt, G Kramer, et al.
Oncoimmunology|July 9, 2015
The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markersHideki Ujiie, Kyuichi Kadota, Jun-Ichi Nitadori, et al.
Chemistry & Biology|January 25, 2005
Specificity and affinity of natural product cyclopentapeptide inhibitors against A. fumigatus, human, and bacterial chitinasesFrancesco V Rao, Douglas R Houston, Rolf G Boot, et al.
Pageof 36

Showing results (171-180 of 360) with videos related to

Sort By:
Pageof 36
Neurobiology of Disease|March 16, 2019
Cytosolic glucosylceramide regulates endolysosomal function in Niemann-Pick type C diseaseSimon Wheeler, Per Haberkant, Meenakshi Bhardwaj, et al.
The Journal of Organic Chemistry|January 25, 2007
Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in manTom Wennekes, Richard J B H N van den Berg, Wilma Donker, et al.
Journal of Lipid Research|April 9, 2020
Skin barrier lipid enzyme activity in Netherton patients is associated with protease activity and ceramide abnormalitiesJeroen van Smeden, Hanin Al-Khakany, Yichen Wang, et al.
Carbohydrate Research|August 9, 2014
Design and synthesis of 4'-O-alkyl-chitobiosyl-4-methylumbelliferone as human chitinase fluorogenic substratesBoudewijn A Duivenvoorden, Karen Ghauharali, Saskia Scheij, et al.
Molecular Genetics and Metabolism|February 24, 2020
Biochemical and imaging parameters in acid sphingomyelinase deficiency: Potential utility as biomarkersEline C B Eskes, Barbara Sjouke, Frédéric M Vaz, et al.
Journal of Inherited Metabolic Disease|September 20, 2007
Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safeJ Cox-Brinkman, R G M Timmermans, F A Wijburg, et al.
Journal of Inherited Metabolic Disease|October 14, 2008
Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type IIIJ Cox-Brinkman, M J van Breemen, B T van Maldegem, et al.
Journal of Proteomics|February 2, 2015
Potential of UCHL1 as biomarker for destruction of pancreatic beta cellsB Brackeva, V De Punt, G Kramer, et al.
Oncoimmunology|July 9, 2015
The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markersHideki Ujiie, Kyuichi Kadota, Jun-Ichi Nitadori, et al.
Chemistry & Biology|January 25, 2005
Specificity and affinity of natural product cyclopentapeptide inhibitors against A. fumigatus, human, and bacterial chitinasesFrancesco V Rao, Douglas R Houston, Rolf G Boot, et al.
Pageof 36